CSS-Assessing the Course of Degenerative Cervical Spinal Stenosis Using Functional Outcomes
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · May 5, 2020
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Study A is a single centre cross-sectional study with two study groups, one that will be treated conservatively (stenosis) and one that will be treated surgically (stenosis and myelopathy).
Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment.
Clinical, radiological, biomechanical (kinematic and electromyographic), neurological and neurophysiological data will be collected. Differences in and the relationship between the clinical, radiological, biomechanical, neurological and neurophysiological data will be de...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years
- • Diagnosis of degenerative cervical spine stenosis defined by MRI (stenosis grade 2 or grade 3
- • Local clinical symptoms due to degenerative changes of the cervical vertebral column with or without clinically defined myelopathy
- Exclusion Criteria:
- • Stenosis after trauma or neoplasm
- • Prior decompressive surgery
- • Previous spine or extremity surgery with a consequent sensorimotor impairment
- • Other pathologies than cervical spine stenosis causing gait disturbance
- • BMI \> 35 kg/m2
- • Use of walking aids
- • Inability to provide informed consent
- • Contraindications for recording of Motor evoked potentials (MEP)
- • Contraindications to safely undergo MRI
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Trial Officials
Annegret Mündermann, Prof. Dr.
Principal Investigator
University Hospital, Basel, Switzerland
Cordula Netzer, Dr. med.
Principal Investigator
University Hospital, Basel, Switzerland
Regina Schläger, PD Dr. med.
Principal Investigator
University Hospital, Basel, Switzerland
Martin Hardmeier, PD Dr. med.
Principal Investigator
University Hospital, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials